The heterozygous familial hypercholesterolemia (HeFH) drug market is anticipated to grow at a considerable CAGR during the forecast period. The prominent factors driving the growth of the market include increasing prevalence of cardio vascular diseases among population due to high consumption of fast and oily foods which is high in cholesterol and lifestyle changes that make people away from physical activities such as exercise. Apart from this, HeFH is caused by a change in a gene that makes it harder for body to remove LDL cholesterol from bloodstream. HeFH affects about 1 out of every 500 people. The rise in adoption of high-level manufacturing technology coupled with combination therapy for treatment of HeFH is likely to accelerate the market gorwth. In line with advances in clinical research and new development in the drug market are giving alternatives for the treatment of FH disease. For instance, in June 2020, adults who have Heterozygous familial hypercholesterolemia can now be treated with Nexlizet for lowering LLP cholesterol.
Browse the full report description of “Global Heterozygous Familial Hypercholesterolemia Drugs Market Size, Share & Trends Analysis Report By Type (Gemcabene Calcium, MGL-3196, ST- 103 and Others), By Application (Hospital, Medical Center, Clinics and Others) Forecast 2022-2028” at https://www.omrglobal.com/industry-reports/heterozygous-familial-hypercholesterolemia-drugs-market
Moreover, acquisition, collaborations & partnerships between key players to facilitate drug development along with improvement in drug quality are the factor boosting the market growth for familial hypercholesterolemia. For instance, in January 2020, Novartis AG acquired The Medicines Company. The acquisition gave a unique opportunity to Novartis to further develop treatment and drugs for atherosclerotic cardiovascular disease or familial hypercholesterolemia.
Market Coverage
• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
o By type
o By Application
• Regions Covered-
o North America
o Europe
o Asia-Pacific
o Rest of the World
• Competitive Landscape- Daewoong Corp.Ltd., Esperion Therapeutics, Inc., Gemphire Therapeutics, Inc., Madrigal Pharmaceuticals Inc., Abbvie Inc., and others
Key questions addressed by the report
• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impact the market?
o Deviation from the pre-COVID-19 forecast
o Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?
Global Heterozygous familial hypercholesterolemia drugs market Report by Segment
By type
By Application
Global Heterozygous familial hypercholesterolemia drugs market Report by Region
North America
• United States
• Canada
Europe
• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe
Asia-Pacific
• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific
Rest of the World
• Latin America
• Middle East & Africa
To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/heterozygous-familial-hypercholesterolemia-drugs-market